In the two years the Life Sciences Industrial Strategy has been in existence, there has been very substantial progress in making the UK
a more attractive place for life sciences companies to succeed and grow.
These developments are the result of a strong collaboration between all aspects of this diverse industry ? pharma, biotech, medtech, digital and diagnostics ? the wider research community in the UK, the NHS and government. Together these parties have identified opportunities and acted on them, and have similarly recognised our limitations and worked to overcome them.
This coalition has made a significant difference to the sector and has also shown what a clear, well?targeted strategy can achieve.
This report describes the progress made against the targets set in the original Life Sciences Industrial Strategy published in August 2017. A substantial majority of the objectives in the Life Sciences Industrial Strategy have been met and more are being delivered now.